These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8562404)

  • 61. Sensitivity to activated protein C; influence of oral contraceptives and sex.
    Henkens CM; Bom VJ; Seinen AJ; van der Meer J
    Thromb Haemost; 1995 Mar; 73(3):402-4. PubMed ID: 7667823
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
    Aparicio C; Dahlbäck B
    Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An epidemiological study of the haemostatic and other effects of oral contraceptives.
    Meade TW; Brozović M; Chakrabarth R; Howarth DJ; North WR; Stirling Y
    Br J Haematol; 1976 Nov; 34(3):353-64. PubMed ID: 990177
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Resistance to activated protein C as a basis for venous thrombosis.
    Svensson PJ; Dahlbäck B
    N Engl J Med; 1994 Feb; 330(8):517-22. PubMed ID: 8302317
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation.
    Váradi K; Rosing J; Tans G; Pabinger I; Keil B; Schwarz HP
    Thromb Haemost; 1996 Aug; 76(2):208-14. PubMed ID: 8865533
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Activation, activity and inactivation of factor VIII in factor VIII products.
    Orfeo T; Elsman R; Gissel M; Mann KG; Butenas S
    Haemophilia; 2016 May; 22(3):462-73. PubMed ID: 26822998
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial.
    Johnson JV; Lowell J; Badger GJ; Rosing J; Tchaikovski S; Cushman M
    Obstet Gynecol; 2008 Feb; 111(2 Pt 1):278-84. PubMed ID: 18238963
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Acquired resistance to activated protein C in pregnancy].
    Schneider DM; von Tempelhoff GF; Hoppenstaedt D; Fareed J; Heilmann L
    Z Geburtshilfe Neonatol; 1998; 202(3):107-10. PubMed ID: 9715525
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Changes in the levels of factor VIII and von Willebrand factor in the puerperium.
    Huq FY; Kulkarni A; Agbim EC; Riddell A; Tuddenham E; Kadir RA
    Haemophilia; 2012 Mar; 18(2):241-5. PubMed ID: 21951573
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
    Svensson PJ; Benoni G; Fredin H; Björgell O; Nilsson P; Hedlund U; Nylander G; Bergqvist D; Dahlbäck B
    Thromb Haemost; 1997 Sep; 78(3):993-6. PubMed ID: 9308742
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pregnancy in women with different types of von Willebrand disease.
    Conti M; Mari D; Conti E; Muggiasca ML; Mannucci PM
    Obstet Gynecol; 1986 Aug; 68(2):282-5. PubMed ID: 3090493
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Activated protein C resistance in normal pregnancy.
    Peek MJ; Nelson-Piercy C; Manning RA; de Swiet M; Letsky EA
    Br J Obstet Gynaecol; 1997 Sep; 104(9):1084-6. PubMed ID: 9307540
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oral contraceptive therapy causes an increased and not a decreased resistance to APC.
    Girolami A; Simioni P; Girolami B; Scarano L; Paolo S [corrected to Simioni P]; Bruno G [corrected to Girolami B]; Luigi S [corrected to Scarano L]
    Blood Coagul Fibrinolysis; 1995 Apr; 6(2):143-4. PubMed ID: 7605882
    [No Abstract]   [Full Text] [Related]  

  • 75. Acquired activated protein C resistance in pregnancy.
    Schlit AF; Col-De Beys C; Moriau M; Lavenne-Pardonge E
    Thromb Res; 1996 Nov; 84(3):203-6. PubMed ID: 8914220
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Increased resistance to activated protein C in women taking third-generation oral contraceptives?
    Gris JC; Nouvellon-Cochery E; Marès P
    Blood; 2004 Sep; 104(6):1907; author reply 1908-9. PubMed ID: 15342364
    [No Abstract]   [Full Text] [Related]  

  • 77. Resistance to activated protein C is reduced in women using oral contraceptives.
    Osterud B; Robertsen R; Asvang GB; Thijssen F
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):853-4. PubMed ID: 7865698
    [No Abstract]   [Full Text] [Related]  

  • 78. The composition of the blood of women during pregnancy and after delivery.
    HOCH H; MARRACK JR
    J Obstet Gynaecol Br Emp; 1948 Feb; 55(1):1-16. PubMed ID: 18902557
    [No Abstract]   [Full Text] [Related]  

  • 79. Inhibitory effects of amniotic fluid on the activated protein C anticoagulation system in maternal plasma.
    Jain D; Oda T; Kawai K; Horikoshi Y; Matsumoto M; Narumi M; Kohmura-Kobayashi Y; Furuta-Isomura N; Yaguchi C; Uchida T; Suzuki K; Kanayama N; Itoh H; Tamura N
    J Thromb Thrombolysis; 2022 Jan; 53(1):208-212. PubMed ID: 34228247
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Thrombin generation test as a marker for high risk venous thrombosis pregnancies.
    Joly BS; Sudrié-Arnaud B; Barbay V; Borg JY; Le Cam Duchez V
    J Thromb Thrombolysis; 2018 Jan; 45(1):114-121. PubMed ID: 29032523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.